Profil
Mel L.
Billingsley is currently the President & Chief Executive Officer at Life Sciences Greenhouse of Central Pennsylvania since 2002.
He is also a Professor at The Pennsylvania State University.
He completed his undergraduate degree from the University of Pittsburgh in 1974 and received his doctorate degree from George Washington University.
Aktive Positionen von Mel L. Billingsley
| Unternehmen | Position | Beginn |
|---|---|---|
Life Sciences Greenhouse of Central Pennsylvania
Life Sciences Greenhouse of Central Pennsylvania Investment ManagersFinance LSGPA invests in companies located in the United States. The firm focuses on drug design, drug delivery systems, biomedical devices, biopharmaceutical manufacturing innovation, drug assay/detection/screening systems and bio nanotechnology. It participates in early-stage capital transactions. | Vorstandsvorsitzender | 01.01.2002 |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Ausbildung von Mel L. Billingsley
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
University of Pittsburgh
University of Pittsburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
George Washington University
George Washington University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Life Sciences Greenhouse of Central Pennsylvania
Life Sciences Greenhouse of Central Pennsylvania Investment ManagersFinance LSGPA invests in companies located in the United States. The firm focuses on drug design, drug delivery systems, biomedical devices, biopharmaceutical manufacturing innovation, drug assay/detection/screening systems and bio nanotechnology. It participates in early-stage capital transactions. | Finance |
















